Congress orders breakup of vertically integrated health giants—forcing insurers to choose: doctors o

What it does

This bill prohibits large health care companies from simultaneously owning insurance companies or pharmacy benefit managers AND owning medical providers (doctors, hospitals, pharmacies). It also bars drug wholesalers from owning medical providers. Companies in violation have one year to divest one side of their business. The bill empowers the FTC, DOJ, state attorneys general, and private citizens to sue for violations, with penalties including 10% monthly profit escrow, treble damages, and forced divestiture overseen by a court-appointed trustee.

Why we flagged it

The bill's core mechanism is a forced divestiture requirement—companies must choose between owning insurers/PBMs or medical providers, not both. This is a structural antitrust remedy, not a price cap or regulatory tweak. The operative text is plain and direct about what it prohibits and what must be divested.

What the text implies

• Divestiture may fragment integrated delivery networks, potentially raising administrative costs for smaller divested entities and reducing their negotiating power with remaining large players—a short-term cost to some providers before market rebalancing.
• The 1-year divestiture deadline is aggressive; companies may be forced to sell assets at fire-sale prices, potentially benefiting private equity acquirers and reducing the divested entity's value to employees and communities.
• The private right of action with treble damages and attorney's fees may trigger a wave of litigation, creating uncertainty and legal costs that could be passed to consumers during the transition period.
• Profit disgorgement into community health funds creates a new discretionary spending stream; implementation and distribution criteria are not specified, raising questions about how funds will actually reach harmed communities.
• The bill does not address whether divested entities must remain independent or can be acquired by other large health care platforms, potentially recreating vertical integration under different ownership.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill directly addresses documented conflicts of interest in vertically integrated health care—where insurers steer patients to their own doctors, PBMs favor their own pharmacies, and wholesalers push lucrative drugs over best treatment. Structural separation reduces these conflicts, potentially lowering drug costs and improving care quality. The enforcement mechanisms (treble damages, private right of action, profit disgorgement to community health funds) create accountability and deterrence

Who stands to gain

• independent physicians and physician practices (reduced competition from integrated platforms)
• independent pharmacies (reduced steering by vertically integrated PBMs)
• private equity firms (potential acquirers of divested assets)
• smaller health insurers and PBMs (reduced competitive pressure from integrated giants)
• specialty drug wholesalers and distributors (reduced steering pressure from integrated wholesalers)

Named in the bill

UnitedHealth Group, Cigna, Anthem, Aetna, CVS Health, Walgreens Boots Alliance, Amazon Pharmacy, Cardinal Health, McKesson, AmerisourceBergen, Federal Trade Commission, Department of Justice Antitrust Division — and 3 more

Where it stands

1 cosponsor: 1 Republicans.

• Feb 10, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Feb 10, 2026 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

20 lobbying clients named this bill on 21 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $33,008,872 in lobbying spend. A filing names 12 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 97% of bills with at least one filing.

Elizabeth Warren, the sponsor, reported $19,000 in PAC receipts in the 2026 cycle.

• Chamber of Commerce of the U.S.A. — $16,950,000 on 1 filing
• American Medical Association — $5,643,000 on 2 filings
• CVS Health (and Subsidiaries) — $3,570,000 on 1 filing
• Pharmaceutical Care Management Association — $3,282,990 on 1 filing
• Healthcare Distribution Alliance (formerly - Hdma) — $567,882 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.